Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia
| Autor: | Rotger, M, Taffe, P, Bleiber, G, Gunthard, HF, Furrer, H, Vernazza, P, Drechsler, H, Bernasconi, E, Rickenbach, M, Telenti, A, Swiss, HIV Cohort Study |
|---|---|
| Přispěvatelé: | University of Zurich, Telenti, Amalio |
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty 610 Medicine & health 142-005 142-005 Gastroenterology Cohort Studies Indinavir Antiretroviral Therapy Highly Active Internal medicine medicine Humans Immunology and Allergy Glucuronosyltransferase Hyperbilirubinemia Unconjugated hyperbilirubinemia business.industry virus diseases Lopinavir 2725 Infectious Diseases Middle Aged Jaundice medicine.disease Gilbert's syndrome Atazanavir Treatment Outcome Infectious Diseases Adult Antiretroviral Therapy Highly Active/*adverse effects Cohort Studies Female Gilbert Disease/*complications Glucuronosyltransferase/*genetics Humans Hyperbilirubinemia/*chemically induced/complications Male Middle Aged Treatment Outcome Immunology 2723 Immunology and Allergy 570 Life sciences biology Female Ritonavir Gilbert Disease medicine.symptom business Saquinavir medicine.drug |
| Zdroj: | Journal of Infectious Diseases, vol. 192, no. 8, pp. 1381-6 Rotger, M; Taffe, P; Bleiber, G; Gunthard, HF; Furrer, H; Vernazza, P; Drechsler, H; Bernasconi, E; Rickenbach, M; Telenti, A; Swiss, HIV Cohort Study (2005). Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. Journal of infectious diseases, 192(8), pp. 1381-6. Cary, N.C.: The University of Chicago Press 10.1086/466531 |
| DOI: | 10.1086/466531 |
| Popis: | BACKGROUND: Unconjugated hyperbilirubinemia results from Gilbert syndrome and from antiretroviral therapy (ART) containing protease inhibitors. An understanding of the interaction between genetic predisposition and ART may help to identify individuals at highest risk for developing jaundice. METHODS: We quantified the contribution of UGT1A1*28 and ART to hyperbilirubinemia by longitudinally modeling 1386 total bilirubin levels in 96 human immunodeficiency virus (HIV)-infected individuals during a median of 6 years. RESULTS: The estimated average bilirubin level was 8.8 micromol/L (0.51 mg/dL). Atazanavir increased bilirubin levels by 15 mu mol/L (0.87 mg/dL), and indinavir increased bilirubin levels by 8 micromol/L (0.46 mg/dL). Ritonavir, lopinavir, saquinavir, and nelfinavir had no or minimal effect on bilirubin levels. Homozygous UGT1A1*28 increased bilirubin levels by 5.2 micromol/L (0.3 mg/dL). As a consequence, 67% of individuals homozygous for UGT1A1*28 and receiving atazanavir or indinavir had > or =2 episodes of hyperbilirubinemia in the jaundice range (>43 micromol/L [>2.5 mg/dL]), versus 7% of those with the common allele and not receiving either of those protease inhibitors (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|